OncohematologyOncohematologyОнкогематология1818-83462413-4023Publishing House ABV Press28510.17650/1818-8346-2018-13-2-21-31HEMATOLOGIC MALIGNANCIES: DIAGNOSIS, TREATMENT, SUPPORTIVE CAREГЕМОБЛАСТОЗЫ: ДИАГНОСТИКА, ЛЕЧЕНИЕ, СОПРОВОДИТЕЛЬНАЯ ТЕРАПИЯCLINICAL CHARACTERISTICS AND TREATMENT RESULTS OF PEDIATRIC RELAPSED/REFRACTORY NON-HODGKIN’S LYMPHOMASКЛИНИЧЕСКАЯ ХАРАКТЕРИСТИКА И РЕЗУЛЬТАТЫ ТЕРАПИИ РЕЦИДИВОВ/РЕФРАКТЕРНЫХ ФОРМ НЕХОДЖКИНСКИХ ЛИМФОМ У ДЕТЕЙ: ОБЗОР ЛИТЕРАТУРЫ И АНАЛИЗ СОБСТВЕННЫХ ДАННЫХhttps://orcid.org/0000-0002-1469-2365ValievT. T.ВалиевТ. Т.
Russian Federation

23 Kashirskoye Shosse, 115478 Moscow

Тимур Теймуразович Валиев

115478 Москва, Каширское шоссе, 23

timurvaliev@mail.ruN.N. Blokhin National Medical Research Center of Oncology, Ministry of Health of Russia, Pediatric Oncology and Hematology Research InstituteФГБУ «НМИЦ онкологии им. Н.Н. Блохина» Минздрава России, НИИ детской онкологии и гематологии1207201813221311307201813072018https://oncohematology.abvpress.ru/ongm/article/view/285

Despite the development and active use of modern high-effective therapeutic protocols for pediatric non-Hodgkin’s lymphomas (NHL), treatment results of relapses and refractory disease are unsatisfactory. In the current issue international practices and own experience in relapsed/refractory pediatric NHL are presented: lymphoblastic lymphomas, anaplastic large cell lymphoma, and heterogeneous group of mature B-cell lymphomas. Chemotherapy protocols, results of nelarabine, rituximab, crizotinib, brentuximab vedotin, stem cell transplantation use for relapsed/refractory pediatric NHL treatment are presented. In 27 relapsed NHL patients treated inN.N.BlokhinNationalMedicalResearchCenterof Oncology, overall survival was 29.1 ± 7.9% (median follow-up 56.3 ± 14.4 months). Primary refractory NHL cases were fatal. Own and literature data make it necessary further study of new therapeutic approaches aimed at improvement of results in relapsed/refractory NHL.

Несмотря на разработку и активное использование современных высокоэффективных протоколов лечения неходжкинских лимфом (НХЛ) у детей, результаты терапии рецидивов и рефрактерных форм остаются неудовлетворительными. В настоящей статье приведен мировой и собственный опыт лечения рецидивов/рефрактерных форм различных вариантов НХЛ у детей: лимфобластных лимфом из клеток-предшественников, анапластической крупноклеточной лимфомы и гетерогенной группы лимфом из зрелых В-клеток. Представлены противорецидивные схемы лечения, результаты использования неларабина, ритуксимаба, кризотиниба, брентуксимаба ведотина, трансплантации гемопоэтических стволовых клеток в лечении рецидивов и рефрактерных форм НХЛ. При анализе терапии рецидивов 27 больных с НХЛ, проходивших лечение в ФГБУ «НМИЦ онкологии им. Н.Н. Блохина» МЗ РФ, показатель общей выживаемости составил 29,1 ± 7,9 % (медиана наблюдения 56,3 ± 14,4 мес). Попытки терапии первично рефрактерного течения НХЛ оказались неудачными. Собственные и литературные данные заставляют проводить дальнейший поиск терапевтических решений, направленных на повышение результатов терапии рецидивов и рефрактерных форм НХЛ.

non-Hodgkin’s lymphomasrelapsetreatmentchildrenнеходжкинские лимфомырецидивылечениедетиValiev T.T., Popa A.V., Levashov A.S. et al. Non-Hodgkin’s Lymphomas in Children: 25-Year Clinical Experience. Klinicheskaya onkogematologiya = Clinical oncohematology 2016;9(4): 420–37 (In Russ.). DOI: 10.21320/2500-2139-2016-9-4-420-437.Валиев Т.Т., Попа А.В., Левашов А.С. и др. Неходжкинские лимфомы у детей: 25 лет терапии. Клиническая онкогематология: Фундаментальные исследования и клиническая практика 2016;9(4):420–37. DOI: 10.21320/2500-2139-2016-9-4-420-437.Kobrinsky N.L., Sposto R., Shah N.R. et al. Outcomes of treatment of children and adolescents with recurrent nonHodgkin’s lymphoma and Hodgkin’s disease with dexamethasone, etoposide, cisplatin, cytarabine, and l-asparaginase, maintenance chemotherapy, and transplantation: Children’s Cancer Group Study CCG-5912. J Clin Oncol 2001;19(9):2390–6. DOI: 10.1200/JCO.2001.19.9.2390. PMID: 11331317Seidemann K., Tiemann M., Schrappe M. et al. Short-pulse B-non-Hodgkin lymphoma-type chemotherapy is efficacious treatment for pediatric anaplastic large cell lymphoma: a report of the Berlin-Frankfurt-Munster Group Trial NHL-BFM 90. Blood 2001;97(12):3699–3706. PMID: 11389005.Woessmann W., Zimmermann M., Lenhard M. et al. Relapsed or refractory anaplastic large-cell lymphoma in children and adolescents after Berlin-FrankfurtMuenster (BFM)-type first-line therapy: a BFM-group study. J Clin Oncol 2011;29(22):3065–71. DOI: 10.1200/JCO.2011.34.8417. PMID: 21709186.Brugieres L., Pacquement H., Le Deley M.C. et al. Single-drug vinblastine as salvage treatment for refractory or relapsed anaplastic large-cell lymphoma: a report from the French Society of Pediatric Oncology. J Clin Oncol 2009;27(30):5056–61. DOI: 10.1200/JCO.2008.20.1764. PMID: 19738127.Garner R., Li Y., Gray B. et al. Long-term disease control of refractory anaplastic large cell lymphoma with vinblastine. J Pediatr Hematol Oncol 2009;31(2):145–7. DOI: 10.1097/MPH.0b013e31819146f8. PMID: 19194204.Griffin T.C., Weitzman S., Weinstein H. et al. A study of rituximab and ifosfamide, carboplatin, and etoposide chemotherapy in children with recurrent/refractoryB-cell (CD20+) non-Hodgkin lymphoma and mature B-cell acute lymphoblastic leukemia: A report from the Childrens Oncology Group. Pediatr Blood Cancer 2009;52(2):177–81. DOI: 10.1002/pbc.21753. PMID: 18816698.Cairo M.S., Sposto R., Hoover-Regan M. et al. Childhood and adolescent large-cell lymphoma (LCL): a review of the Children’s Cancer Group experience. Am J Hematol 2003;72(1):53–63. DOI: 10.1002/ajh.10262. PMID: 12508269.Fujita N., Mori T., Mitsui T. et al. The role of hematopoietic stem cell transplantation with relapsed or primary refractory childhood B-cell non-Hodgkin lymphoma and mature B-cell leukemia: A retrospective analysis of enrolled cases in Japan. Pediatric Blood Cancer 2008;51(2):188–192. DOI: 10.1002/pbc.21585. PMID: 18428432.Michaux K., Bergeron C., Gandemer V. et al. Relapsed or Refractory Lymphoblastic Lymphoma in Children: Results and Analysis of 23 Patients in the EORTC 58951 and the LMT96 Protocols. Pediatr Blood Cancer 2016;63(7):1214–21. DOI: 10.1002/pbc.25990. PMID: 27037853.Tallen G., Ratei R. Mann G. et al. Longterm outcome in children with relapsed acute lymphoblastic leukemia after timepoint and site-of-relapse stratification and intensified short-course multidrug chemotherapy: results of trial ALL-REZ BFM 90. J Clin Oncol 2010;28(14):2339–47. DOI: 10.1200/JCO.2009.25.1983. PMID: 20385996.Lambe C.U., Averett D.R., Paff M.T. et al. 2-Amino-6-methoxypurine arabinoside: an agent for T-cell malignancies. Cancer Res 1995;55(15):3352–6. PMID: 7614470.Mori T., Takimoto T., Katano N. et al. Recurrent childhood anaplastic large cell lymphoma: a retrospective analysis of registered cases in Japan. Br J Haematol 2006;132(5):594–7. DOI: 10.1111/j.1365-2141.2005.05910.x. PMID: 16445832.Brugières L., Quartier P., Le Deley M.C. et al. Relapses of childhood anaplastic large-cell lymphoma: treatment results in a series of 41 children--a report from the French Society of Pediatric Oncology. Ann Oncol 2000;11(1):53–8. PMID: 10690387.Pro B., Advani R., Brice P. et al. Brentuximab vedotin (SGN-35) in patients with relapsed or refractory systemic anaplastic large-cell lymphoma: results of a phase II study. J Clin Oncol 2012;30(18):2190–6. DOI: 10.1200/JCO.2011.38.0402. PMID: 22614995.Cooper T.M., Razzouk B.I., Gerbing R. et al. Phase I/II trial of clofarabine and cytarabine in children with relapsed/refractory acute lymphoblastic leukemia (AAML0523): a report from the Children’s Oncology Group. Pediatr Blood Cancer 2013;60(7):1141–7. DOI: 10.1002/pbc.24398. PMID: 23335239.Cairo M.S. Monoclonal antibody and targeted cellular immunotherapy for childhood, adolescent and young adult lymphoma. British Journal of Haematology 2012;159(Suppl. 1):11.Sampson B., Triche L., Rytting M. Brentuximab vedotin (SGN 35): prolonged remission in a teen-ager with multiply relapsed Anaplastic Large Cell Lymphoma. British Journal of Haematology 2012;159(Suppl. 1):62.Gambacorti P.C., Farina F., Stasia A. et al. Crizotinib in Advanced, Chemoresistant Anaplastic Lymphoma Kinase-Positive Lymphoma Patients. J Natl Cancer Inst 2014;106(2):378. DOI: 10.1093/jnci/djt378. PMID: 24491302.Akbayram S., Doğan M., Akgün C. et al. Use of rituximab in three children with relapsed/refractory Burkitt lymphoma. Targeted Oncology 2010; 5(4): 291–4. DOI: 10.1007/s11523-010-0161-6. PMID: 20859698.Harris R.E., Termuhlen A.M., Smith L.M. et al. Autologous peripheral blood stem cell transplantation in children with refractory or relapsed lymphoma: results of Children,s Oncology Group Study A5962. Biol Blood Marrow Transplant 2011;17(2):249–58. DOI: 10.1016/j. bbmt.2010.07.002. PMID: 20637881.Holmberg L.A., Maloney D., Bensinger W. Immunotherapy with rituximab/interleukin-2 after autologous stem cell transplantation as treatment for CD20+ non-Hodgkin’s lymphoma. Clin Lymphoma Myeloma 2006;7(2):135–9. DOI: 10.3816/CLM.2006.n.051. PMID: 17026825.Jourdain A., Auperin A., Minard-Colin V. et al. Outcome of and prognostic factors for relapse in children and adolescents with mature B-cell lymphoma and leukemia treated in three consecutive prospective “Lymphomes Malins B” protocols. A Société Française des Cancers de l’Enfant study. Haematologica. 2015;100(6):810–17. DOI: 10.3324/haematol.2014.121434. PMID: 25724577.Cooney-Qualter E., Krailo M., Angiolillo A. et al. A Phase I Study of 90Yttrium-Ibritumomab-Tiuxetan in Children and Adolescents with Relapsed/Refractory CD20Positive Non-Hodgkin’s Lymphoma: A Children’s Oncology Group Study. Clin Cancer Res 2007; 13(18 Pt 2): 5652s– 5660s. DOI: 10.1158/1078-0432.CCR-071060. PMID: 17875803.Kurtzberg J., Ernst T.J., Keating M.J. et al. Phase I study of 506U78 administered on a consecutive 5day schedule in children and adults with refractory hematologic malignancies. J Clin Oncol 2005;23(15):3396–403. DOI: 10.1200/JCO.2005.03.199. PMID: 15908652.Rodriguez C.O., Jr., Stellrecht C.M., Gandhi V. Mechanisms for T-cell selective cytotoxicity of arabinosylguanine. Blood 2003;102(5):1842–8. DOI: 10.1182/blood-2003-01-0317. PMID: 12750168.Cohen M.H., Johnson J.R., Massie T. et al. Approval summary: nelarabine for the treatment of T-cell lymphoblastic leukemia/lymphoma. Clin Cancer Res 2006;12(18):5329–35. DOI: 10.1158/1078-0432.CCR-06-0606. PMID: 17000665.Hazar V., Kesik V., Karasu G.T. et al. Risk factors predicting the survival of pediatric patients with relapsed/refractory nonHodgkin lymphoma who underwent hematopoietic stem cell transplantation: a retrospective study from the Turkish pediatric bone marrow transplantation registry. Leuk Lymphoma 2018;59(1):85–96. DOI: 10.1080/10428194.2017.1330472. PMID: 28571522.Woessmann W., Zimmermann M., Lenhard M. et al. Relapsed or refractory anaplastic large-cell lymphoma in children and adolescents after Berlin-FrankfurtMuenster (BFM)-type first-line therapy: a BFM-group study. J Clin Oncol 2011;29(22):3065–71. DOI: 10.1200/JCO.2011.34.8417. PMID: 21709186.Giulino-Roth L., Ricafort R., Kernan N.A. et al. Ten-year follow-up of pediatric patients with non-Hodgkin lymphoma treated with allogeneic or autologous stem cell transplantation. Pediatr Blood Cancer 2013; 60(12): 2018–24. DOI: 10.1002/pbc.24722. PMID: 24038967.Sekimizu M., Iguchi A., Mori T. et al. Phase I clinical study of brentuximab vedotin (SGN-35) involving children with recurrent or refractory CD30-positive Hodgkin's lymphoma or systemic anaplastic large cell lymphoma: rationale, design and methods of BV-HLALCL study: study protocol. BMC Cancer 2018;18(1):122. DOI: 10.1186/s12885-018-4042-1. PMID: 29390984.Mikles B., Levine J., Gindin T. et al. Brentuximab vedotin (SGN-35) in a 3-year-old child with relapsed systemic anaplastic large cell lymphoma. J Pediatr Hematol Oncol 2014;36(2):e85–7. DOI: 10.1097/MPH.0b013e31828aff2c. PMID: 23588340.Mossé Y.P., Voss S.D., Lim M.S. et al. Targeting ALK With Crizotinib in Pediatric Anaplastic Large Cell Lymphoma and Inflammatory Myofibroblastic Tumor: A Children’s Oncology Group Study. J Clin Oncol 2017;35(28):3215–21. DOI: 10.1200/JCO.2017.73.4830. PMID: 28787259.Turner S.D., Lamant L., Kenner L. et al. Anaplastic large cell lymphoma in paediatric and young adult patients. Br J Haematol 2016;173(4):560–72. DOI: 10.1111/bjh.13958. PMID: 26913827.Foyil K.V., Bartlett N.L. Brentuximab vedotin and crizotinib in anaplastic large-cell lymphoma. Cancer J 2012; 18(5): 450– 456. DOI: 10.1097/PPO.0b013e31826aef4a. PMID: 23006951.Okur F.V., Oguz A., Karadeniz C. et al. Refractoriness to rituximab monotherapy in a child with relapsed/refractory Burkitt non-Hodgkin lymphoma. Pediatr Hematol Oncol 2006,23(1):25–31. DOI: 10.1080/08880010500313298. PMID: 16326409.Montagut C., Rovira A., Albanell J. The proteasome: a novel target for anticancer therapy. Clin Transl Oncol 2006;8(5):313–7. PMID: 16760005.Lee A.H., Iwakoshi N.N., Anderson K.C. et al. Proteasome inhibitors disrupt the unfolded protein response in myeloma cells. Proc Natl Acad Sci USA 2003;100(17): 9946–51. DOI: 10.1073/pnas.1334037100. PMID: 12902539.Nencioni A., Grunebach F., Patrone F. et al. Proteasome inhibitors: antitumor effects and beyond. Leukemia 2007; 21(1):30–6. DOI: 10.1038/sj.leu.2404444. PMID: 17096016.Ruschak A.M., Slassi M., Kay L.E. et al. Novel proteasome inhibitors to overcome bortezomib resistance. J Natl Cancer Inst 2011;103(13):1007–17. DOI: 10.1093/jnci/djr160. PMID: 21606441.Dick L.R., Fleming P.E. Building on bortezomib: second-generation proteasome inhibitors as anticancer therapy. Drug Discov Today 2010;15(5–6):243–9. DOI: 10.1016/j.drudis.2010.01.008. PMID: 20116451.Hideshima T., Ikeda H., Chauhan D. et al. Bortezomib induces canonical nuclear factor-kappaB activation in multiple myeloma cells. Blood 2009;114(5):1046–52. DOI: 10.1182/blood-2009-01-199604. PMID: 19436050.Li C., Chen S., Yue P. et al. Proteasome inhibitor PS-341 (bortezomib) induces calpain-dependent IkappaB(alpha) degradation. J Biol Chem 2010;285(21):16096– 104. DOI: 10.1074/jbc.M109.072694. PMID: 20335171.Messinger Y., Gaynon P., Raetz E. et al. Phase I study of bortezomib combined with chemotherapy in children with relapsed childhood acute lymphoblastic leukemia (ALL): a report from the therapeutic advances in childhood leukemia (TACL) consortium. Pediatr Blood Cancer 2010;55(2):254–9. DOI: 10.1002/pbc.22456. PMID: 20582937.Rytting M., Triche L., Thomas D. et al. Initial experience with CMC-544 (inotuzumab ozogamicin) in pediatric patients with relapsed B-cell acute lymphoblastic leukemia. Pediatr Blood Cancer 2014;61(2):369–72. DOI: 10.1002/pbc.24721. PMID: 24000241.Swerdlow S.H., Campo E., Harris N.L. et al. WHO Classification of Tumours of Haematopoetic and Lymphoid tissues, 4th еd. International Agency for Research on Cancer. Lyon, 2008. Р. 439.Woessmann W., Seidemann K., Mann G. et al. The impact of the methotrexate administration schedule and dose in the treatment of children and adolescents with B-cell neoplasms: a report of the BFM Group Study NHL-BFM95. Blood 2005; 105(3):948–58. DOI: 10.1182/blood-2004-03-0973. PMID: 15486066.Volejnikova J., Jarosova M., Pospisilova D. et al. Treatment and prognosis of childhood acute lymphoblastic leukemia on protocols ALL-BFM 90, 95 and ALL ICBFM 2002: a retrospective single-center study from Olomouc, Czech Republic. Neoplasma 2016;63(3):456–61. DOI: 10.4149/316_150910N482. PMID: 26925793.Stary J., Zimmermann M., Campbell M. et al. Intensive chemotherapy for childhood acute lymphoblastic leukemia: results of the randomized intercontinental trial ALL IC-BFM 2002. J Clin Oncol 2014;32(3):174–84. DOI: 10.1200/JCO.2013.48.6522. PMID: 24344215.Huang S., Jin L., Yang J. et al. Clinical pathologic characteristics and treatment outcomes of 19 relapsed pediatric B-cell lymphoma. Zhonghua Er Ke Za Zhi 2017;55(10):748–53. DOI: 10.3760/cma.j.issn.0578-1310.2017.10.007. PMID: 29050112.